Remove Innovation Remove Kidney Disease Remove Obesity
article thumbnail

The Cardiometabolic Event of the Year: What to Expect at the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

This fall, we come together for the largest and most innovative cardiometabolic event in honor of the legacy of Dr. George L. Practical, Future-Focused Education Cardiorenal and metabolic diseases, fueled by poor lifestyle choices and health conditions, lead to type 2 diabetes, cardiovascular disease, and chronic kidney disease.

Education 100
article thumbnail

19th Annual Cardiometabolic Health Congress: Honoring the Life and Legacy of CMHC Co-Chair Dr. George L. Bakris

Cardiometabolic Health Congress

This October, we gather for the largest and most innovative cardiometabolic event, honoring Dr. Bakris’ profound impact on our community. Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. To apply, click here or go to www.cardiometabolichealth.org/george-bakris-scholarship-program/ NEW!

CME 72
article thumbnail

Top 10 Cardiac Diagnosis Trends in 2024

GEMMS

In this article, we will explore the top 10 trends shaping the future of cardiovascular medicine, highlighting the innovative technologies and approaches that are revolutionizing the field. Genetic testing and DNA sequencing improve the accuracy of predicting heart disease risk.

article thumbnail

From NASH to MASH: New Terms for Liver Diseases Unveiled at the 2023 Cardiometabolic Health Congress

Cardiometabolic Health Congress

A session at the 18 th Annual Cardiometabolic Health Congress (CMHC), explored the intersection of cardiometabolic conditions such as obesity and insulin resistance with liver disease, beginning with some important new updates on the preferred terms for these diseases. Nonalcoholic fatty liver disease (NAFLD) & NASH.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,

CME 103